This resource library contains information for prescribers, including resources to support patients and their caregivers.
A Quick guide to the VOXZOGO® PBS authority prescribing codes
Select the correct dose for your patient and learn how it is administered
This guide will familiarise you with administration so you can help patients and caregivers feel comfortable with daily injections.
The study was an open-label, phase 3 extension study aimed to evaluate the safety and efficacy of long-term treatment with vosoritide in children with achondroplasia. (Ravi et al, 2021)
This multinational, Phase 2, dose-finding study with a following extension study evaluated the safety and side-effect profile of vosoritide in 35 children with achondroplasia. (Ravi et al, 2019)
This pivotal trial to investigated the safety and efficacy of once-daily subcutaneous injections of vosoritide in children with achondroplasia, with the primary endpoint as the change from baseline in mean annualised growth velocity at 52 weeks in treated patients as compared with controls. (Ravi et al, 2020)
This study explored the perceived impact of achondroplasia on medical complications, HRQoL, healthcare resource use and mortality, and potential modifying effects of vosoritide, based on published evidence and expert opinion. (Ravi et al, 2022)
Everything your patient needs to get started with VOXZOGO, contained within a cooler bag: sharps container, alcohol wipes, band-aids, laminated injection calendar and other useful information.
This flyer describes the support and resources available for patients who have been prescribed VOXZOGO®
This brochure provides information for families on achondroplasia, how VOXZOGO® works, and how to prepare and administer daily injections and should be read in conjunction with the Consumer Medicine Information
To talk to a healthcare professional for help with injection technique call 1800 418 385 or email voxzogo@cpharm.com.au
myVOXZOGO App is designed to support caregivers and children who are being treated with VOXZOGO®. The app provides personalised tools and resources to suit your patients’ needs.
Please contact us for more information.
BRINEURA® is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
KUVAN® is indicated for the treatment of hyperphenylalaninemia (HPA) in sapropterin-responsive adult and paediatric patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.
NAGLAZYME® is indicated as long term enzyme replacement therapy in patients with Mucopolysaccharidosis VI (MPS VI, Nacetylgalactosamine 4- sulfatase deficiency, Maroteaux-Lamy syndrome).
VIMIZIM® is indicated for the treatment of MPS IVA (Mucopolysaccharidosis type IVA, morquio A syndrome).
VOXZOGO® is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.